Aspira Women's Health 2023 rev $9.2M (+15% YoY); cash burn halved to $15.9M

Aspira Women's Health Inc.

Q4 product revenue $2.1M flat YoY; OvaSuite volume ~5,659 tests.
Full year 2023 OvaSuite volume 23,990 units (+12% YoY); AUP $382.
Cash used in operations $15.9M for 2023, down 49% from $31.1M in 2022.
Gross margin improved to 57.5% from 52.8% on lower lab/shipping costs.
Raised $5.5M in registered direct offering post year-end; cash $2.9M at Dec 31.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Aspira Women's Health Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue Product revenue was $2.1 million for the three months ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Revenue: Product revenue was $2.1 million for the three months ended December 31, 2023
Result: reported results

Exact text from the filing

Aspira Women’s Health Inc. (the “Company”) issued a press release reporting financial results for the three and twelve months ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-24-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.